<?xml version="1.0" encoding="UTF-8"?>
<p>The hepatitis C epidemic is similarly geographically diverse and mode of transmission differs substantially between regions.
 <xref rid="liv14222-bib-0011" ref-type="ref">11</xref>, 
 <xref rid="liv14222-bib-0012" ref-type="ref">12</xref>, 
 <xref rid="liv14222-bib-0013" ref-type="ref">13</xref>, 
 <xref rid="liv14222-bib-0014" ref-type="ref">14</xref> Globally, an estimated 52% of people who inject drugs (PWID) are hepatitis C antibody positive.
 <xref rid="liv14222-bib-0015" ref-type="ref">15</xref> Lack of access to needle and syringe programmes (NSPs) and opioid antagonist treatment (OAT) result in unsafe injecting practices, which are the major route of transmission in high‐income countries.
 <xref rid="liv14222-bib-0015" ref-type="ref">15</xref>, 
 <xref rid="liv14222-bib-0016" ref-type="ref">16</xref> In low‐ and middle‐income countries, additional transmission occurs in healthcare settings through substandard infection control practices.
 <xref rid="liv14222-bib-0017" ref-type="ref">17</xref>
</p>
